Stockreport

Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Clearside Biomedical, Inc.  (CLSD) 
Last clearside biomedical, inc. earnings: 3/11 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.clearsidebio.com/investor-overview
PDF - Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention-Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development - - Unique Abil [Read more]